1. Market Research
  2. > Pharmaceutical Market Trends
  3. > LigoCyte Pharmaceuticals, Inc. - Product Pipeline Review - 2013

LigoCyte Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 18 pages

LigoCyte Pharmaceuticals, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “LigoCyte Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the LigoCyte Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, LigoCyte Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from LigoCyte Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- LigoCyte Pharmaceuticals, Inc. - Brief LigoCyte Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of LigoCyte Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of LigoCyte Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the LigoCyte Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate LigoCyte Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of LigoCyte Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the LigoCyte Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with LigoCyte Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of LigoCyte Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

LigoCyte Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
LigoCyte Pharmaceuticals, Inc. Snapshot 4
LigoCyte Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
LigoCyte Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
LigoCyte Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
LigoCyte Pharmaceuticals, Inc. - Pipeline Products Glance 9
LigoCyte Pharmaceuticals, Inc. - Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
LigoCyte Pharmaceuticals, Inc. - Drug Profiles 10
Influenza VLP vaccine 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
Respiratory Syncytial Virus-Virus Like Particle Vaccine 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
LigoCyte Pharmaceuticals, Inc. - Pipeline Analysis 12
LigoCyte Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 12
LigoCyte Pharmaceuticals, Inc. - Recent Pipeline Updates 13
LigoCyte Pharmaceuticals, Inc. - Dormant Projects 15
LigoCyte Pharmaceuticals, Inc. - Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
Coverage 17
Secondary Research 17
Primary Research 17
Expert Panel Validation 17
Contact Us 18
Disclaimer 18

List of Tables


LigoCyte Pharmaceuticals, Inc., Key Information 4
LigoCyte Pharmaceuticals, Inc., Key Facts 4
LigoCyte Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
LigoCyte Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
LigoCyte Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
LigoCyte Pharmaceuticals, Inc. - Pre-Clinical, 2013 9
LigoCyte Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 12
LigoCyte Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 13
LigoCyte Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 15

List of Figures


LigoCyte Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
LigoCyte Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
LigoCyte Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
LigoCyte Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 12

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.